New Mexico Allocates $630K for Medical Psilocybin Treatment Equity Fund

SANTA FE – Gov. Michelle Lujan Grisham signed the state’s annual budget bill, setting aside $630,000 to create the Medical Psilocybin Treatment Equity Fund and extend access to supervised psilocybin therapy for low-income and rural New Mexicans.

The allocation appears in House Bill 2 and backs a provision written into the New Mexico Medical Psilocybin Act, which the Legislature passed in 2025. That law established a regulated program allowing qualified patients to receive psilocybin-assisted therapy for treatment-resistant depression (TRD), post-traumatic stress disorder (PTSD), substance use disorders, and end-of-life distress. The equity fund, housed in the state treasury, will help cover treatment costs for patients who meet income criteria set by the Department of Health.

State health officials aim to enroll the first patients by the end of 2026, roughly a year ahead of the statutory deadline. The Psilocybin Advisory Board is now drafting rules on everything from facility standards and facilitator training to dosing protocols and safety measures. New Mexico would become the third state with a supervised psilocybin program, after Oregon and Colorado, but the first to dedicate public dollars specifically to income-based access.

Advocates from groups including the Healing Advocacy Fund pressed lawmakers during the budget process after initial proposals left the fund unfunded. Denali Wilson, the group’s New Mexico director of strategic support, called the money “the beginning of a bold new chapter in state-led health innovation.” Sen. Jeff Steinborn, a sponsor of the original act, said the step ensures the program serves the communities it was designed to reach.

The fund’s creation reflects a practical recognition that a full course of psilocybin therapy can cost thousands of dollars per patient, putting it out of reach for many in a state where rural poverty rates remain high. It remains to be seen whether the initial $630,000 will be sufficient, as this amount largely depends on the final per-treatment costs and patient volume once the program opens.

The move marks a measured advance in integrating emerging therapies into public health infrastructure. Implementation details (licensing, reimbursement rates, and rural delivery models) will ultimately determine how many patients gain meaningful access. Early data from other states suggest psilocybin therapy can deliver durable symptom relief in carefully screened populations, but real-world outcomes in a government-run equity framework remain unproven. Regulators and providers will have roughly nine months to translate legislative intent into operational reality.